Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) dropped 4.7% during trading on Friday . The stock traded as low as $30.11 and last traded at $30.13. Approximately 303,617 shares were traded during mid-day trading, a decline of 53% from the average daily volume of 640,214 shares. The stock had previously closed at $31.63.
Analysts Set New Price Targets
IART has been the subject of several research reports. JMP Securities reduced their target price on Integra LifeSciences from $55.00 to $49.00 and set a "market outperform" rating for the company in a research report on Thursday, February 29th. Truist Financial reduced their target price on Integra LifeSciences from $46.00 to $41.00 and set a "hold" rating for the company in a research report on Friday, March 1st. Citigroup upgraded Integra LifeSciences from a "sell" rating to a "neutral" rating and set a $38.00 price objective for the company in a research note on Wednesday, April 3rd. Finally, StockNews.com lowered Integra LifeSciences from a "buy" rating to a "hold" rating in a research note on Friday, April 5th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $44.89.
Read Our Latest Research Report on IART
Integra LifeSciences Stock Performance
The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of 33.99, a price-to-earnings-growth ratio of 0.96 and a beta of 1.12. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.45 and a quick ratio of 2.18. The stock has a 50 day moving average price of $37.12 and a two-hundred day moving average price of $39.14.
Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share for the quarter, missing analysts' consensus estimates of $0.90 by ($0.01). Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The business had revenue of $397.00 million during the quarter, compared to analyst estimates of $399.30 million. During the same quarter last year, the business posted $0.94 earnings per share. The business's quarterly revenue was down .3% compared to the same quarter last year. On average, analysts predict that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current fiscal year.
Institutional Trading of Integra LifeSciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IART. Raymond James & Associates increased its position in Integra LifeSciences by 24.5% in the first quarter. Raymond James & Associates now owns 40,457 shares of the life sciences company's stock worth $2,600,000 after purchasing an additional 7,971 shares during the period. MetLife Investment Management LLC boosted its holdings in Integra LifeSciences by 33.4% during the first quarter. MetLife Investment Management LLC now owns 47,096 shares of the life sciences company's stock worth $3,026,000 after buying an additional 11,796 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in Integra LifeSciences by 10.5% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 26,696 shares of the life sciences company's stock worth $1,715,000 after buying an additional 2,546 shares during the last quarter. Great West Life Assurance Co. Can boosted its holdings in Integra LifeSciences by 8.0% during the first quarter. Great West Life Assurance Co. Can now owns 40,012 shares of the life sciences company's stock worth $2,643,000 after buying an additional 2,969 shares during the last quarter. Finally, Yousif Capital Management LLC boosted its holdings in Integra LifeSciences by 6.5% during the first quarter. Yousif Capital Management LLC now owns 40,207 shares of the life sciences company's stock worth $2,584,000 after buying an additional 2,466 shares during the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.
About Integra LifeSciences
(
Get Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Further Reading
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
